Όλο το DSpace

Πλοήγηση ανά Θέμα "Antirheumatic Agents"

Αποτελέσματα 1-13 από 13

    • Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis 

      Vasilopoulos, Y.; Bagiatis, V.; Stamatopoulou, D.; Zisopoulos, D.; Alexiou, I.; Sarafidou, T.; Settas, L.; Sakkas, L.; Mamuris, Z. (2011)
      Objective: To investigate the possible influence of tumour necrosis factoralpha (TNF), TNF receptor I (TNFRI) and TNF receptor II (TNFRII) gene polymorphisms on anti-TNF treatment responsiveness, stratified by autoantibody ...

    • Curcumin for the management of periodontitis and early ACPA-positive rheumatoid arthritis: Killing two birds with one stone 

      Asteriou E., Gkoutzourelas A., Mavropoulos A., Katsiari C., Sakkas L.I., Bogdanos D.P. (2018)
      We propose curcumin as a preventive measure to avoid/manage periodontitis (PD), and as a natural immunosuppressant for rheumatoid arthritis (RA). PD, mainly caused by Porphyromonas gingivalis forming biofilm and leading ...

    • Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept 

      Ferreiro-Iglesias A., Montes A., Perez-Pampin E., Cañete J.D., Raya E., Magro-Checa C., Vasilopoulos Y., Caliz R., Ferrer M.A., Joven B., Carreira P., Balsa A., Salcedo D.P., Blanco F.J., Moreno-Ramos M.J., Manrique-Arija S., Del Carmen Ordonez M., Alegre-Sancho J.J., Narvaez J., Navarro-Sarabia F., Moreira V., Valor L., Garcia-Portales R., Marquez A., Gomez-Reino J.J., Martin J., Gonzalez A. (2019)
      Research in rheumatoid arthritis (RA) is increasingly focused on the discovery of biomarkers that could enable personalized treatments. The genetic biomarkers associated with the response to TNF inhibitors (TNFi) are among ...

    • IL-10 producing Bregs are impaired in psoriatic arthritis and psoriasis and inversely correlate with IL-17- and IFNγ-producing T cells 

      Mavropoulos A., Varna A., Zafiriou E., Liaskos C., Alexiou I., Roussaki-Schulze A., Vlychou M., Katsiari C., Bogdanos D.P., Sakkas L.I. (2017)
      Our aim was to study CD19(+)CD27(+)CD24(high) memory and CD19(+)CD24(high)CD38(high) transitional and IL-10 + Breg cells, known to inhibit Th1 and Th17 cells in experimental arthritis, in psoriatic arthritis (PsA) and ...

    • Incidence, risk factors and validation of the RABBIT score for serious infections in a cohort of 1557 patients with rheumatoid arthritis 

      Thomas K., Lazarini A., Kaltsonoudis E., Voulgari P.V., Drosos A.A., Repa A., Sali A.M.I., Sidiropoulos P., Tsatsani P., Gazi S., Evangelia A., Boki K.A., Katsimbri P., Boumpas D., Fragkiadaki K., Tektonidou M.G., Sfikakis P.P., Karagianni K., Sakkas L.I., Grika E.P., Vlachoyiannopoulos P.G., Evangelatos G., Iliopoulos A., Dimitroulas T., Garyfallos A., Melissaropoulos K., Georgiou P., Areti M., Georganas C., Vounotrypidis P., Georgiopoulos G., Kitas G.D., Vassilopoulos D. (2021)
      Objectives: Predicting serious infections (SI) in patients with rheumatoid arthritis (RA) is crucial for the implementation of appropriate preventive measures. Here we aimed to identify risk factors for SI and to validate ...

    • Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment 

      Ceccarelli F., Perricone C., Cipriano E., Massaro L., Natalucci F., Capalbo G., Leccese I., Bogdanos D., Spinelli F.R., Alessandri C., Valesini G., Conti F. (2017)
      Objective In the present review, the different phenotypes, clinimetric and imaging tools able to assess joint involvement in patients affected by Systemic Lupus Erythematosus (SLE) have been described and summarized. ...

    • Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients 

      Laskari K., Tektonidou P.M.G., Katsiari P.C., Athanassiou P., Dimopoulou D., Gerodimos C., Salamaliki C., Papagoras P.C., Settas P.L., Vassilopoulos P.D., Voulgari P.P.V., Zakalka M., Georgiadis A., Gkoni G., Daoussis P.D., Dimitroulas P.T., Iliou C., Kallitsakis I., Grika E.P., Mavragani P.C., Pikazis P.D., Raftakis J., Sarikoudis T., Kougkas N., Soukera D., Theodorou E., Tsatsani P., Tsiakou E., Vlachoyiannopoulos P.P., Vosvotekas G., Sfikakis P.P.P. (2021)
      Objective: To assess the efficacy and safety of the IL-1b inhibitor canakinumab in all adults with refractory Still's disease identified from the National Organization For Medicines for off-label drug use. Methods

    • Primary sjögren’s syndrome and cardiovascular disease 

      Melissaropoulos K., Bogdanos D., Dimitroulas T., Sakkas L.I., Kitas G.D., Daoussis D. (2020)
      Sjögren’s syndrome is a rheumatic autoimmune disease that primarily affects middle-aged women and runs a slowly progressing course with sicca symptoms being the prevalent manifestation. Premature atherosclerosis and increased ...

    • Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis 

      Ferreiro-Iglesias A., Montes A., Perez-Pampin E., Cañete J.D., Raya E., Magro-Checa C., Vasilopoulos Y., Sarafidou T., Caliz R., Ferrer M.A., Joven B., Carreira P., Balsa A., Pascual-Salcedo D., Blanco F.J., Moreno-Ramos M.J., Fernández-Nebro A., Ordóñez M.C., Alegre-Sancho J.J., Narváez J., Navarro-Sarabia F., Moreira V., Valor L., García-Portales R., Marquez A., Martin J., Gómez-Reino J.J., Gonzalez A. (2016)
      Genetic biomarkers could be useful for orienting treatment of patients with rheumatoid arthritis (RA), but none has been convincingly validated yet. Putative biomarkers include 14 single nucleotide polymorphisms that have ...

    • The risk of lymphoma development in autoimmune diseases: A meta-analysis 

      Zintzaras, E.; Voulgarelis, M.; Moutsopoulos, H. M. (2005)
      Background: The risk of development of non-Hodgkin lymphoma (NHL) in autoimmune patients has been investigated in several cohort studies. These studies revealed inconclusive results. To shed some light on this controversy, ...

    • Should patients with rheumatic diseases take pain medication in order to engage in exercise? 

      Metsios G.S., Kitas G.D. (2020)
      [No abstract available]

    • Upadacitinib tartrate in rheumatoid arthritis 

      Stamatis P., Bogdanos D.P., Sakkas L.I. (2020)
      does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the ...

    • Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis 

      Lopez-Rodriguez R., Perez-Pampin E., Marquez A., Blanco F.J., Joven B., Carreira P., Ferrer M.A., Caliz R., Valor L., Narvaez J., Cañete J.D., Del Carmen Ordoñez M., Manrique-Arija S., Vasilopoulos Y., Balsa A., Pascual-Salcedo D., Moreno-Ramos M.J., Alegre-Sancho J.J., Navarro-Sarabia F., Moreira V., Garcia-Portales R., Raya E., Magro-Checa C., Martin J., Gomez-Reino J.J., Gonzalez A. (2018)
      Genetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, ...